Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.
Although if approved, it's not likely to launch in the U.S. for quite some time.
For all the talk about new and better ways to engage, pharma still hasn't created an appreciably higher volume of satisfied — or informed — customers.
How can pharma brands actionize the data they are collecting? Larry Dobrow, MM&M senior editor, and Patrick Richard, EVP and managing director, data sciences, Syneos Health, weigh in on leveraging data and analytics in this video, sponsored by Syneos.
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
The CEO of the independent healthcare agency discusses growing a business in digital in the early 2000s and the perks of remaining independent.
In an effort to assure advertisers and agencies on brand safety, Google has announced two new requirements for video creators that intend to join the YouTube Partner Program.
Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer
Sigurdsson is charged with leading the agency's digital offering to meet growing client demand.
Merck's Keytruda combo therapy succeeds in Phase-III lung cancer trial; FDA launches pilot to address trial transparency; Spark's Luxturna overpriced, ICER says
Facebook's decision to reprioritise its news feed to favour "social interactions" over other forms of content may please its users but will be challenging for brands.
Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds
The founder of Stagwell has claimed digital marketing agencies are undervalued because investors still fail to appreciate how much digital communications and e-commerce are going to transform the economy.
Once Attorney General Jeff Sessions reversed the Cole memo, NORML began applying pressure both locally and nationally for changes in marijuana laws.
Collecting and analyzing data is a contentious question. High-profile data mavens offered some possible answers yesterday at the JP Morgan Healthcare Conference.
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday's events.
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market